{"url_path":"/sec/dyn/8-k/2026-06-22/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1818794/0001818794-26-000005-index.html","accession_number":"0001818794-26-000005","cik":"0001818794","ticker":"DYN","issuer_name":"Dyne Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818794/0001818794-26-000005-index.html","primary_entity_key":"0001818794","primary_entity_name":"Dyne Therapeutics, Inc."},"word_count":438,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn June 22, 2026, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. Mr. Greene has not been appointed to serve on any committees of the Board. The Board has determined that Mr. Greene is an “independent” director under the Nasdaq Stock Market rules.\n\nMr. Greene shall be entitled to receive compensation under the Company’s non-employee director compensation program. In accordance with this program, upon his election to the Board, Mr. Greene received, under the Company’s 2020 Stock Incentive Plan, an option to purchase 57,463 shares of the Company’s common stock at an exercise price equal to $20.87 per share, the closing price of the Company’s common stock on the date of grant, which option will vest and become exercisable in equal monthly installments over the next three years, subject to his continued service. In the event of a change in control of the Company, the vesting schedule of the option will accelerate in full. In addition, Mr. Greene will receive annual cash compensation of $45,000 as a member of the Board, annual equity grants in accordance with the non-employee director compensation program and reimbursement for reasonable travel and out-of-pocket expenses incurred in connection with attending Board meetings.\n\nThere are no arrangements or understandings between Mr. Greene and any other persons pursuant to which he was elected as a director. Mr. Greene does not have any family relationships with any of the Company’s directors or executive officers. There are no transactions and no proposed transactions between Mr. Greene and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.\n\nMr. Greene will enter into the Company’s standard form of indemnification agreement. The form of the indemnification agreement was filed as Exhibit 10.10 to the Company’s Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission on August 25, 2020.\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDYNE THERAPEUTICS, INC.\n\n \n\n \n\n \n\nDate: June 22, 2026\n\nBy:\n\n/s/ John G. Cox\n\n \n\n \n\nName:\n\nJohn G. Cox\n\n \n\n \n\nTitle:\n\nPresident and Chief Executive Officer"}